Pictet Asset Management Ltd. Buys 308,100 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Pictet Asset Management Ltd. raised its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 8.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,779,942 shares of the biopharmaceutical company’s stock after purchasing an additional 308,100 shares during the quarter. Pictet Asset Management Ltd. owned 1.64% of Amicus Therapeutics worth $47,174,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently modified their holdings of FOLD. Dimensional Fund Advisors LP grew its holdings in Amicus Therapeutics by 374.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,098,083 shares of the biopharmaceutical company’s stock worth $10,518,000 after buying an additional 866,793 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Amicus Therapeutics by 9.0% during the 4th quarter. Geode Capital Management LLC now owns 2,183,679 shares of the biopharmaceutical company’s stock worth $20,919,000 after acquiring an additional 180,938 shares during the last quarter. Strs Ohio boosted its holdings in Amicus Therapeutics by 176.9% during the 1st quarter. Strs Ohio now owns 10,800 shares of the biopharmaceutical company’s stock worth $146,000 after acquiring an additional 6,900 shares during the last quarter. BNP Paribas Arbitrage SA grew its stake in shares of Amicus Therapeutics by 907.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 44,227 shares of the biopharmaceutical company’s stock worth $601,000 after acquiring an additional 39,835 shares in the last quarter. Finally, Bank of Montreal Can grew its stake in shares of Amicus Therapeutics by 2,637.6% in the 1st quarter. Bank of Montreal Can now owns 93,844 shares of the biopharmaceutical company’s stock worth $1,276,000 after acquiring an additional 90,416 shares in the last quarter.

In other news, CEO John F. Crowley sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $12.54, for a total transaction of $250,800.00. Following the completion of the sale, the chief executive officer now owns 770,194 shares in the company, valued at approximately $9,658,232.76. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Burke W. Whitman purchased 4,945 shares of the firm’s stock in a transaction dated Friday, August 23rd. The shares were bought at an average price of $10.07 per share, with a total value of $49,796.15. Following the purchase, the director now owns 21,612 shares in the company, valued at $217,632.84. The disclosure for this purchase can be found here. 2.50% of the stock is owned by insiders.

FOLD has been the topic of a number of recent analyst reports. ValuEngine lowered shares of Amicus Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Monday, August 12th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $19.00 price objective (down from $20.00) on shares of Amicus Therapeutics in a research report on Wednesday, June 5th. HC Wainwright reiterated a “buy” rating and issued a $18.00 price objective on shares of Amicus Therapeutics in a research note on Thursday, August 1st. Cowen reiterated a “buy” rating and issued a $31.00 price objective on shares of Amicus Therapeutics in a research note on Thursday, August 1st. Finally, BidaskClub cut shares of Amicus Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 6th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $18.06.

Shares of Amicus Therapeutics stock traded up $0.05 during trading hours on Wednesday, hitting $9.99. 798,622 shares of the company’s stock traded hands, compared to its average volume of 3,806,391. Amicus Therapeutics, Inc. has a 12-month low of $8.27 and a 12-month high of $14.61. The stock has a market capitalization of $2.42 billion, a price-to-earnings ratio of -7.51 and a beta of 1.65. The company has a fifty day simple moving average of $10.78 and a 200-day simple moving average of $12.28. The company has a debt-to-equity ratio of 0.31, a current ratio of 7.09 and a quick ratio of 6.97.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.34). The company had revenue of $44.13 million for the quarter, compared to the consensus estimate of $41.14 million. Amicus Therapeutics had a negative net margin of 336.41% and a negative return on equity of 66.79%. The firm’s quarterly revenue was up 107.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.33) EPS. On average, analysts forecast that Amicus Therapeutics, Inc. will post -1.33 EPS for the current fiscal year.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.

Recommended Story: How to interpret Moving Average Convergence Divergence (MACD)

Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD).

Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.